Real-world drug survival of bimekizumab, guselkumab and risankizumab after secondary IL-17 inhibitor failure

Published: 5 May 2026| Version 1 | DOI: 10.17632/xbnnmnhkpf.1
Contributor:
Ioannis-Alexios Koumprentziotis

Description

Supplementary Table 1. Univariable and multivariable Cox regression analysis for drug discontinuation after switching.

Files

Categories

Biologic Agent, Psoriasis

Licence